华熙生物PDRN创新技术突破 推动行业从“随机提取”向“精准研发”升级

Core Insights - Huaxi Biological Technology Co., Ltd. has achieved a significant breakthrough in the field of bioactive repair components with the public disclosure of a patent for "specific sequence nucleic acid molecules and their application as PDRN" [1] - The new patent introduces a novel specific sequence PDRN (polydeoxyribonucleotide) with stable biological activity, molecular weight, and product quality, marking the third generation of technology in the PDRN field for the company [1] Summary by Sections Patent and Technology Breakthrough - The core achievement of the patent is a new specific sequence PDRN with 100% similarity to the GC content of the human genome, eliminating reliance on animal extraction and ensuring a more stable raw material source [1] - The new technology overcomes traditional animal-derived PDRN limitations, offering controllable sequences and significantly improved purity [1] Applications and Industry Impact - The patent is expected to provide revolutionary solutions for high-end cosmetic repair and medical wound healing sectors, emphasizing three core advantages: controllable sequences, safety, and enhanced efficacy [1] - The previous microbial fermentation-based PDRN production method yielded products with a GC content of 39.5% to 41.5%, closely resembling human GC content at 40% [2] Research and Development Innovations - The company utilized an AI-assisted high-throughput screening approach to identify multiple PDRN sequences from a database of over 60,000 genomic sequences, ensuring high safety and effectiveness in promoting vascular endothelial growth factor (VEGF) expression [2] - The patent also outlines a simple preparation method for specific sequence PDRN, with a fully controllable production process that aligns with sustainable development goals [2] - The establishment of a theoretical and product system linking "sequence and efficacy" will facilitate the industry's transition from random extraction to precise research and development, promoting standardization and high-quality growth in the bioactive component sector [2]